中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共2条，第1-2条 帮助

已选(0)清除 条数/页：   排序方式：
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial 期刊论文
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 18
作者:  Li, Ning;  Zhu, Jianqing;  Yin, Rutie;  Wang, Jing;  Pan, Lingya;  Kong, Beihua;  Zheng, Hong;  Liu, Jihong;  Wu, Xiaohua;  Wang, Li;  Huang, Yi;  Wang, Ke;  Zou, Dongling;  Zhao, Hongqin;  Wang, Chunyan;  Lu, Weiguo;  Lin, An;  Lou, Ge;  Li, Guiling;  Qu, Pengpeng;  Yang, Hongying;  Zhen, Xiaoa;  Hang, Wenzhao;  Hou, Jianmei;  Banerjee, Ashish;  Wu, Lingying
收藏  |  浏览/下载：33/0  |  提交时间：2022/12/23
Efficacy of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer in phase 3 PRIME study: A subgroup analysis by response to first-line platinum-based chemotherapy. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Yin, Rutie;  Li, Ning;  Wu, Lingying;  Wang, Jing;  Zhu, Jianqing;  Pan, Lingya;  Kong, Beihua;  Zheng, Hong;  Liu, Jihong;  Wu, Xiaohua;  Wang, Li;  Huang, Yi;  Wang, Ke;  Zou, Dongling;  Zhao, Hongqin;  Wang, Chunyan;  Lu, Weiguo;  Zhen, Xiaoa;  Hang, Wenzhao;  Hou, Jianmei
收藏  |  浏览/下载：33/0  |  提交时间：2022/12/23